Will TrovaGene Be an "ASCO Effect" Beneficiary?By William Patalon III, Executive Editor, Money Morning • May 17, 2016 View Comments Start the conversationLeave a Reply Click here to cancel reply.Your email address will not be published. Required fields are marked *Name * Email * Website 9 × 6 = Comment Some HTML is OK Sign me up for the Money Morning newsletter William Patalon IIIShares of TrovaGene Inc. (Nasdaq: TROV) surged more than 9% Friday and as much as 13.5% Monday after the Liquid Biopsy biotech company announced that a TrovaGene scientist presented clinical research findings at a prestigious cancer-treatment symposium in Florida.With biotechs, these presentations can have an outsized impact on a company's share price.This is premium content for Private Briefing subscribers only. As the executive editor of Money Morning, Bill Patalon has perfected a secret investment strategy that could help you put an extra $125K into your portfolio - this year. To date, Bill has used this strategy to pick 257 winning investments, including 192 double- and triple-digit peak gains. Once you see the secret, you'll immediately understand why it works so well.